Effects of poloxamer 188 on human PMN cells

Surgery

Volumn 144, Issue 2, 2008, Pages 198-203

  Harting, Matthew T ^a   Jimenez, Fernando ^a   Kozar, Rosemary A ^a   Moore, Frederick A ^b   Mercer, David W ^a   Hunter, Robert L ^a   Cox Jr , Charles S ^a   Gonzalez, Ernest A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CELL ADHESION MOLECULE; POLOXAMER; SUPEROXIDE;

ARTICLE; BLOOD SAMPLING; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD11B; HUMANS; L-SELECTIN; NEUTROPHILS; POLOXAMER; RESPIRATORY BURST; SUPEROXIDES; SURFACE-ACTIVE AGENTS;

EID: 47549113852     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.05.001     Document Type: Article

References (17)

1. Moore F.A., and Moore E.E. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 75 (1995) 257-277
2. Lenz A., Franklin G.A., and Cheadle W.G. Systemic inflammation after trauma. Injury 38 (2007) 1336-1345
3. Botha A.J., Moore F.A., Moore E.E., Fontes B., Banerjee A., and Peterson V.M. Postinjury neutrophil priming and activation states: therapeutic challenges. Shock 3 (1995) 157-166
4. Botha A.J., Moore F.A., Moore E.E., Kim F.J., Banerjee A., and Peterson V.M. Postinjury neutrophil priming and activation: an early vulnerable window. Surgery 118 (1995) 358-364 discussion 64-5
5. Jewell R.C., Khor S.P., Kisor D.F., LaCroix K.A., and Wargin W.A. Pharmacokinetics of RheothRx injection in healthy male volunteers. J Pharm Sci 86 (1997) 808-812
6. Orringer E.P., Casella J.F., Ataga K.I., et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA 286 (2001) 2099-2106
7. Grindel J.M., Jaworski T., Emanuele R.M., and Culbreth P. Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharm Drug Dispos 23 (2002) 87-103
8. Hymes A.C., Safavian M.H., and Gunther T. The influence of an industrial surfactant Pluronic F-68, in the treatment of hemorrhagic shock. J Surg Res 11 (1971) 191-197
9. Edwards C.M., May J.A., Heptinstall S., and Lowe K.C. Effects of pluronic F-68 (poloxamer 188) on platelet aggregation in human whole blood. Thromb Res 81 (1996) 511-512
10. Mayer D.C., Strada S.J., Hoff C., Hunter R.L., and Artman M. Effects of poloxamer 188 in a rabbit model of hemorrhagic shock. Ann Clin Lab Sci 24 (1994) 302-311
11. Schaer G.L., Hursey T.L., Abrahams S.L., et al. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function. Circulation 90 (1994) 2964-2975
12. Schaer G.L., Spaccavento L.J., Browne K.F., et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation 94 (1996) 298-307
13. Haneda K H.K., Kanno M., Murakami S., and Ohta M. Use of Fluosol DA (FDA) in hemorrhagic shock: Effects on oxygen carrying capacity and peripheral perfusion (1983), Alan R. Liss, New York
14. Tan J., and Saltzman W.M. Influence of synthetic polymers on neutrophil migration in three-dimensional collagen gels. J Biomed Mater Res 46 (1999) 465-474
15. Lane T.A., and Lamkin G.E. Paralysis of phagocyte migration due to an artificial blood substitute. Blood 64 (1984) 400-405
16. Lane T.A., and Lamkin G.E. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood 68 (1986) 351-354
17. Babbitt D.G., Forman M.B., Jones R., Bajaj A.K., and Hoover R.L. Prevention of neutrophil-mediated injury to endothelial cells by perfluorochemical. Am J Pathol 136 (1990) 451-459